Weight change and androgen levels during contraceptive treatment of women affected by polycystic ovary

Endocrine Regulations

Volumn 40, Issue 4, 2006, Pages 119-123

  Vrbíková, Jana ^a   Dvorakova, K ^a   Hill, M ^a   Starka, L ^a  

^a INSTITUTE OF ENDOCRINOLOGY   (Czech Republic)

Author keywords

Androgen; Cyproterone acetate; Insulin resistance; Lipid levels; Polycystic ovary syndrome; SHBG

Indexed keywords

ANDROSTENEDIONE; CHOLESTEROL; DIANE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PRASTERONE SULFATE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CLINICAL ARTICLE; DRUG EFFECT; ENDOCRINE FUNCTION; FEMALE; HORMONE BLOOD LEVEL; HUMAN; LIPID BLOOD LEVEL; MENSTRUATION; OVARY POLYCYSTIC DISEASE; TREATMENT RESPONSE;

ADULT; ANDROGENS; BODY WEIGHT; CONTRACEPTION; CONTRACEPTIVES, ORAL, COMBINED; CYPROTERONE ACETATE; DRUG COMBINATIONS; ETHINYL ESTRADIOL; FEMALE; HUMANS; LIPIDS; POLYCYSTIC OVARY SYNDROME; WEIGHT GAIN;

EID: 33846015014     PISSN: 12100668     EISSN: 13360329     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. BURKMAN RT, JR: The role of oral contraceptives in the treatment of hyperandrogenic disorders. Am J Med 98, 130S-136S, 1995
2. IAMPELLI M, FULGHESCU AM, F. CUCINELLI F et al: Impact of insulin and body mass index on metabolic and endocrine variables in polycystic ovary syndrome. Metabolism 48, 167-172, 1999
3. IBULA D, HILL M, FANTA M et al.: Does obesity diminish the positive effect of oral contraceptive treatment on hyperandrogenism in women with polycystic ovarian syndrome? Hum Reprod 16, 940-944, 2001
4. REATSAS G, KOLIOPOULOS C, MASTORAKOS G: Combined oral contraceptive treatment of adolescent girls with polycystic ovary syndrome. Lipid profile. Ann N Y Acad Sci 900, 245-52, 2000
5. ARNEY PD: The androgenicity of progestins. Am J Med 98, 104S-110S, 1995
6. FALSETTI L, GAMBERA A, TISI G: Efficacy of the combination ethinyl oestradiol and cyproterone acetate on endocrine, clinical and ultrasonographic profile in polycystic ovarian syndrome. Hum Reprod 16, 36-42, 2001
7. FALSETTI L, PASINETTI E: Effects of long-term administration of an oral contraceptive containing ethinylestradiol and cyproterone acetate on lipid metabolism in women with polycystic ovary syndrome. Acta Obstet Gynecol Scand 74, 56-60, 1995
8. GOLLAND IM, ELSTEIN ME: Results of an open one-year study with Diane-35 in women with polycystic ovarian syndrome. Ann N Y Acad Sci 687, 263-71, 1993
9. NESTLER JE: Sex hormone-binding globulin: a marker for hyperinsulinemia and/or insulin resistance? J Clin Endocrinol Metab 76, 273-274., 1993
10. PASQUALI R, GAMBINERI A, ANCONETALI B et al.: The natural history of the metabolic syndrome in young women with the polycystic ovary syndrome and the effect of long-term oestrogen-progestagen treatment. Clin Endocrinol 50, 517-527, 1999
11. PRELEVIC GM, M. I. WURZBURGER I, D. TRPKOVIC D: Effects of a low-dose estrogen-antiandrogen combination (Diane-35) on lipid and carbohydrate metabolism in patients with polycystic ovary syndrome. Gynecol Endocrinol 4, 157-168, 1990
12. REGIDOR PA, SPEER K, REGIDOR M: Long-term side-effects following cyproterone acetate containing therapy in gynecology]. Zentralbl Gynakol 122, 268-273, 2000
13. EXIAU P, VEXIAU-ROBERT D, MARTINEAU I et al.: Metabolic effect at six and twelve months of cyproterone acetate (2 mg) combined with ethinyl estradiol (35 micrograms) in 31 patients. Horm Metab Res 22, 241-5, 1990